Literature DB >> 16433443

[Spinal muscular atrophy. A 4-year prospective, multicenter, longitudinal study (168 cases)].

Annie Barois1, Michèle Mayer, Isabelle Desguerre, Brigitte Chabrol, Carole Berard, Jean-Marie Cuisset, Danielle Leclair-Richard, Jacqueline Visconti-Lougovoy, Françoise Hatton, Brigitte Estournet-Mathiaud.   

Abstract

Spinal muscular atrophy (SMA) is an autosomal recessive neuromuscular disorder characterised by motoneuron degeneration in the anterior horn of the spinal cord and in the bulbar nuclei. The various types of SMA are linked to the 5q13 locus in 95 % of cases. In the absence of an effective specific treatment, orthopaedic and respiratory management can significantly improve the prognosis. To study the contemporary natural history of SMA and to identify clinical and non invasive prognostic criteria, 168 patients with SMA were recruited in 6 hospital units (Lille, Lyon, Marseille, Paris) during a 4-year prospective multicenter follow-up study (1998-2002). Follow-up has now lasted at least 4 years in 151 cases (90%), and 24 of these patients have died Disease outcome was appraised by using three criteria: muscle strength, the sum of the motor function and examination index (IFM), the respiratory muscle paralysis index (IMR), and the dorsal decubitus forced vital capacity/theoretical index (ICV/CT). Statistical analysis showed a significant worsening (about 20%) of the three criteria during follow-up. The motor function and examination index (IFM) is particularly interesting: the difference between initial and final status was significant in all age groups and in all three types of the disease. The IFM may thus be useful as the main outcome measure during therapeutic trials.

Entities:  

Mesh:

Year:  2005        PMID: 16433443

Source DB:  PubMed          Journal:  Bull Acad Natl Med        ISSN: 0001-4079            Impact factor:   0.144


  5 in total

1.  Issues in SMA clinical trial design. The International Coordinating Committee (ICC) for SMA Subcommittee on SMA Clinical Trial Design.

Authors:  P Kaufmann; F Muntoni
Journal:  Neuromuscul Disord       Date:  2007-02-14       Impact factor: 4.296

2.  Observational study of spinal muscular atrophy type 2 and 3: functional outcomes over 1 year.

Authors:  Petra Kaufmann; Michael P McDermott; Basil T Darras; Richard Finkel; Peter Kang; Maryam Oskoui; Andrei Constantinescu; Douglas Michael Sproule; A Reghan Foley; Michele Yang; Rabi Tawil; Wendy Chung; Bill Martens; Jacqueline Montes; Jessica O'Hagen; Sally Dunaway; Jean M Flickinger; Janet Quigley; Susan Riley; Allan M Glanzman; Maryjane Benton; Patricia A Ryan; Carrie Irvine; Christine L Annis; Hailly Butler; Jayson Caracciolo; Megan Montgomery; Jonathan Marra; Benjamin Koo; Darryl C De Vivo
Journal:  Arch Neurol       Date:  2011-02-14

3.  Reliability of four tests to assess body posture and the range of selected movements in individuals with spinal muscular atrophy.

Authors:  Agnieszka Stępień; Maria Jędrzejowska; Katarzyna Guzek; Witold Rekowski; Jolanta Stępowska
Journal:  BMC Musculoskelet Disord       Date:  2019-02-07       Impact factor: 2.362

4.  [Rare diseases and their clinical oral manifestations in two Hospitals in Yaoundé].

Authors:  Hubert Désiré Mbassi Awa; Rose Mbédé Nga Mvondo; Séraphin Nguefack; Charles Bengondo Messanga; Paul Olivier Koki Ndombo
Journal:  Pan Afr Med J       Date:  2019-04-22

Review 5.  The SMA Clinical Trial Readiness Program: creation and evaluation of a program to enhance SMA trial readiness in the United States.

Authors:  Ilse Peterson; Rosángel Cruz; Fatou Sarr; Ann Marie Stanley; Jill Jarecki
Journal:  Orphanet J Rare Dis       Date:  2020-05-22       Impact factor: 4.123

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.